dresselstyn.com 的前十大競爭對手

nutritionstudies.org

T. Colin Campbell, PhD is the Professor Emeritus of Nutritional Biochemistry at Cornell University. Dr. Campbell’s scientific interests include the relationship between diet and disease, and causation of cancer. His legacy, the China Project, is one of the most comprehensive studies of health and nutrition ever conducted. He founded the Plant-Based Nutrition Certificate.

choose-healthy-eating-for-life.com

Starting a new year always brings new plans that we hope to keep. Why not include a healthy living plan to stay young, healthy and active?

hpjmh.com

Click Here for My Original Full-Size Blog Since 2011 Link to weekly SOS Memos and Bite-Size Blogs since 2016  Beginning on February 9, 2011, I posted a daily full-size blog for 737 consecutive day…

thepaleodiet.com

Whether you're new to The Paleo Diet or a long-time follower, this 2-page printable shopping list of Paleo Diet foods will make grocery shopping easier! Updated and improved.

precisionnutrition.com

Precision Nutrition is the home of the world's top nutrition coaches. Best-in-class nutrition coaching, nutrition software, and professional certification.

chriskresser.com

There is an undeniable connection between nutrition and healthy skin. In this ebook you will learn how skin conditions can be treated through nutrition.

jnm.snmjournals.org

Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)–positive cases. We use a pretargeted radioimmunotherapy (PRIT) approach consisting of a 3-step intravenous regimen (step 1: bispecific anti-HER2/anti-DOTA antibody; step 2: clearing agent; step 3: 225Ac-radiolabeled Proteus DOTA, or [225Ac]Ac-Pr). Our goal was to establish curative 225Ac-PRIT with high therapeutic indices. Methods: The impact of [225Ac]Ac-Pr specific activity was evaluated in the BT-474 breast xenograft model. We tested the effects of [225Ac]Ac-Pr dosing during PRIT on tumor-targeting efficiency and tissue biodistribution. Using a 225Ac-PRIT regimen consisting of a ratio of 1.19 nmol of bispecific antibody to 0.60–0.66 nmol of [225Ac]Ac-Pr, we evaluated therapy in the BT-474 model and a patient-derived xenograft model. BT-474-tumor–bearing mice were treated with 1 or 2 cycles of 225Ac-PRIT (37 kBq/cycle) separated by 1 wk. A dose escalation study was performed on the BT-474 model to establish an absorbed radiation dose of approximately 40 Gy (relative biological effectiveness [RBE], 5) as a nephrotoxic dose, as no such histologic findings were observed in prior studies at the 20.7-Gy (RBE, 5) renal dose level. Results: In the BT-474 model, 100% (20/20) achieved complete responses and histologic cure in 17 of 20 (85%) of the treated animals. One-cycle and 2-cycle treatments were equally effective. Treatments were well tolerated, with no chronic radiation toxicity documented during necropsy at 175 d. Dosimetry estimates (RBE, 5) per 37 kBq administered for tumors and kidneys were 210 and 3.5 Gy, respectively. In the patient-derived xenograft model, a single 225Ac-PRIT treatment led to 60% (3/5) complete response and prolonged survival (>93 d) versus no treatment (30 d; P = 0.0185). Lastly, a 225Ac-PRIT regimen was identified that induces severe chronic nephrotoxicity (41.4